Sonnet BioTherapeutics Shares Are Trading Higher After the Company's Phase 1b/2a Clinical Trial of SON-080 Was Cleared to Proceed to Phase 2 After Review by an Independent DSMB
Sonnet BioTherapeutics股價走高,此前該公司的 SON-080 1b/2a期臨床試驗經獨立DSMB審查後獲准進入第二階段
Sonnet BioTherapeutics Shares Are Trading Higher After the Company's Phase 1b/2a Clinical Trial of SON-080 Was Cleared to Proceed to Phase 2 After Review by an Independent DSMB
Sonnet BioTherapeutics股價走高,此前該公司的 SON-080 1b/2a期臨床試驗經獨立DSMB審查後獲准進入第二階段
使用瀏覽器的分享功能,分享給你的好友吧